This is the largest and most updated assessment to date on the efficacy of GLP-1 RAs to specifically treat NAFLD or NASH that has also included the most recently published RCTs using two long-acting GLP-1 RAs, such as dulaglutide and semaglutide [33,34]. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.